This piece offers a sharp critique of mainstream Alzheimer’s research, arguing that the amyloid hypothesis — which has dominated the field for decades — has produced expensive drugs with limited benefits while potentially sidelining other promising avenues.
What’s worth considering:
- The amyloid theory has indeed faced major setbacks and high-profile research scandals.
- Available Alzheimer’s drugs have shown only modest clinical benefits for many patients, often at very high cost and with significant side effects.
- Metabolic, vascular, and inflammatory factors appear to play important roles in cognitive decline.
Important Caution: While the article raises legitimate questions about institutional bias and financial incentives in medical research, it leans heavily toward conspiracy framing and promotes certain alternative treatments that, while interesting, generally lack large-scale, rigorous clinical evidence.
Bottom Line: If you or a loved one are dealing with Alzheimer’s or cognitive decline, this article can serve as one perspective worth reading. However, it should not replace professional medical advice. Traditional medicine, while imperfect, remains the foundation for most patients. For those who feel standard approaches are not sufficient, exploring metabolic or alternative strategies under medical supervision may be worth discussing with a knowledgeable physician.
This piece is archived here as part of our ongoing health library — useful for reference and discernment as new information emerges.